BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma

Published: Jan 21, 2022 | Tags: BMS, Abecma, idecabtagene vicleucel, MHLW, Approval, Multiple Myeloma

ASLAN Reports First Patient Enrollment in P-IIb (TREK-AD) Study of ASLAN004 (eblasakimab) for the Treatment of Atopic Dermatitis

Published: Jan 21, 2022 | Tags: ASLAN, P-IIb, TREK-AD Study, ASLAN004, eblasakimab, Atopic Dermatitis

Provention Bio Initiates P-IIa (PREVAIL-2) Study of PRV-3279 for the Treatment of Systemic Lupus Erythematosus

Published: Jan 21, 2022 | Tags: Provention Bio, P-IIa, PREVAIL-2 Study, PRV-3279, Systemic Lupus Erythematosus

Turning Point Reports the US FDA’s IND Clearance of Elzovantinib + Aumolertinib for EGFR Mutant Met-Amplified NSCLC

Published: Jan 21, 2022 | Tags: Turning Point, US, FDA, IND, Elzovantinib, Aumolertinib, EGFR Mutant, Met-Amplified, NSCLC

Merck and Eisai Presents Results of Keytruda (pembrolizumab) + Lenvima (lenvatinib) in P-III (KEYNOTE-775/Study 309) Trial for Advanced EC

Published: Jan 21, 2022 | Tags: Merck, Eisai, Keytruda, pembrolizumab, Lenvima, Lenvatinib, P-III, KEYNOTE-775, Study 309 Trial, Advanced EC

Eleusis Going Public via Silver Spike SPAC Merger for ~$446M

Published: Jan 21, 2022 | Tags: Eleusis, Going Public, Silver Spike, SPAC, Merger, ~$446M

Sema4 Signs a Definitive Agreement to Acquire GeneDx for ~$623M

Published: Jan 20, 2022 | Tags: Sema4, Acquire, GeneDx, ~$623M

Amgen’s Lumakras (sotorasib) Receives MHLW Approval for the Treatment of Advanced Non-Small Cell Lung Cancer

Published: Jan 20, 2022 | Tags: Amgen, Lumakras, sotorasib, MHLW, Approval, Non-Small Cell Lung Cancer

Vera Seeks to Initiate P-III Clinical Trial of Atacicept for the Treatment of Lupus Nephritis

Published: Jan 20, 2022 | Tags: Vera, P-III, Clinical Trial, Atacicept, Lupus Nephritis

ChemoCentryx’s Tavneos (avacopan) Receives EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis

Published: Jan 20, 2022 | Tags: ChemoCentryx, Tavneos, avacopan, EU, Approval, Tavneos, avacopan, ANCA-Associated Vasculitis

Regeneron Reports the US FDA Acceptance of sBLA for Review of Libtayo (cemiplimab) to Treat Advanced Non-Small Cell Lung Cancer

Published: Jan 20, 2022 | Tags: Regeneron, US, FDA, sBLA, Review, Libtayo, cemiplimab, Non-Small Cell Lung Cancer

AstraZeneca Reports Results of Imfinzi + tremelimumab in P-III (HIMALAYA) Trial for the Treatment of Hepatocellular Carcinoma

Published: Jan 20, 2022 | Tags: AstraZeneca, Imfinzi, tremelimumab, P-III, HIMALAYA Trial, Hepatocellular Carcinoma

UCB Signs a Definitive Agreement to Acquire Zogenix for ~$1.9B

Published: Jan 19, 2022 | Tags: UCB, Acquire, Zogenix, ~$1.9B

Sanofi Reports Results of Dupixent (dupilumab) in P-III (PRIME) Trial for the Treatment of Prurigo Nodularis

Published: Jan 19, 2022 | Tags: Sanofi, Dupixent, dupilumab, P-III, PRIME Trial, Prurigo Nodularis

Exelixis Presents Results for Cabozantinib in P-Ib (COSMIC-021) & P-II (CAMILLA) Trial for Advanced Colorectal Cancer at ASCO GI 2022

Published: Jan 19, 2022 | Tags: Exelixis, Cabozantinib, P-Ib, COSMIC-021, P-II, CAMILLA Trial, Advanced Colorectal Cancer,  ASCO GI 2022

23andMe Extends its 2018 Collaboration with GSK for CD96 Program to Treat Cancer

Published: Jan 19, 2022 | Tags: 23andMe, 2018, GSK, CD96 Program, Cancer

AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III (TOPAZ-1) Trial as 1L Treatment of Advanced Biliary Tract Cancer

Published: Jan 19, 2022 | Tags: AstraZeneca, Imfinzi, durvalumab, P-III, TOPAZ-1 Trial, Advanced Biliary Tract Cancer

Merck Presents Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-394) Trial for the Treatment of Advanced HCC at ASCO GI 2022

Published: Jan 19, 2022 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-394 Trial, Advanced, HCC, ASCO GI 2022

ADC Entered an Exclusive License Agreement with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Japan

Published: Jan 18, 2022 | Tags: ADC, Mitsubishi Tanabe Pharma Corporation, Zynlonta, loncastuximab tesirine-lpyl, Japan

Lilly Entered into a Collaboration with Evotec to Develop Therapies for Diabetes and Chronic Kidney Diseases

Published: Jan 18, 2022 | Tags: Lilly, Evotec, Diabetes, Chronic Kidney Diseases

Pfizer’s Paxlovid (nirmatrelvir and ritonavir) Receives Health Canada’s Approval for the Treatment of COVID-19

Published: Jan 18, 2022 | Tags: Pfizer, Paxlovid, nirmatrelvir, ritonavir, Health Canada, Approval, COVID-19

Lilly Entered into an Exclusive License Agreement with Abbisko to Develop Novel Therapies for Cardiometabolic Diseases

Published: Jan 18, 2022 | Tags: Lilly, Abbisko, Novel Therapies, Cardiometabolic Diseases

Neurimmune Expands its Collaboration with Ono to Develop Monoclonal Antibody Therapies for the Treatment of Neurodegenerative Diseases

Published: Jan 18, 2022 | Tags: Neurimmune, Ono, Antibody Therapies, Neurodegenerative Diseases, RTM Technology Platform

CANbridge Reports NMPA Acceptance of NDA for AN108 to Treat Alagille  Syndrome

Published: Jan 18, 2022 | Tags: CANbridge, NMPA, NDA, AN108, Alagille Syndrome

Ascletis’s ASC22 (envafolimab) Receives US FDA’s IND Approval of ASC22 (envafolimab) for the Treatment of Chronic Hepatitis B

Published: Jan 17, 2022 | Tags: Ascletis, ASC22, envafolimab, US, FDA, IND, Approval, ASC22, envafolimab, Chronic Hepatitis B

Medtronic Reports Three Months Results of DTM Spinal Cord Stimulation Endurance Therapy for the Treatment of Chronic Pain

Published: Jan 17, 2022 | Tags: Medtronic, DTM Spinal Cord Stimulation Endurance Therapy, Chronic Pain

Pfizer’s Cibinqo (abrocitinib) Receives the US FDA’s Approval for the Treatment of Atopic Dermatitis

Published: Jan 17, 2022 | Tags: Pfizer, Cibinqo, abrocitinib, US, FDA, Approval, Atopic Dermatitis

AstraZeneca Reports Results of Vaxzevria as Third Dose Booster in Multiple Trial for the Treatment of COVID-19

Published: Jan 17, 2022 | Tags: AstraZeneca, Vaxzevria, D7220C00001 Trial, COVID-19

Dermavant Reports Results of Tapinarof in P-III (PSOARING 3) Study for the Treatment of Plaque Psoriasis

Published: Jan 17, 2022 | Tags: Dermavant, Tapinarof, P-III, PSOARING 3 Study, Plaque Psoriasis

AbbVie’s Rinvoq (upadacitinib) Receives the US FDA’s Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Published: Jan 17, 2022 | Tags: AbbVie, Rinvoq, upadacitinib, US, FDA, Approval, Atopic Dermatitis

Related Post: PharmaShots Weekly Snapshots (January 10 - 14, 2022)